Document is current
Any future updates will be listed below
-
Authors
Ko, Julie
Winslow, Monte M https://orcid.org/0000-0002-5730-9573
Sage, Julien https://orcid.org/0000-0002-8928-9968
-
Funding
Funding for this research was provided by:
HHS | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R35 CA231997)
- License Information
-
More Information
Article History
Received: 15 July 2020
Revised: 2 November 2020
Accepted: 5 November 2020
First Online: 9 December 2020
Conflicts of interests
: J.S. receives research funding from Stemcentrx/Abbvie and Pfizer, and licensed a patent to Forty Seven Inc./Gilead on the use of CD47 blocking strategies in SCLC. M.M.W. has equity in, and is an advisor for, D2G Oncology Inc.
:
:
